Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

854 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. Among authors: porter b. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group. Marzo-Ortega H, et al. Among authors: porter b. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7. Arthritis Care Res (Hoboken). 2017. PMID: 28235249 Free PMC article. Clinical Trial.
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.
Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D. Braun J, et al. Among authors: porter b. Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1. Arthritis Res Ther. 2019. PMID: 31174584 Free PMC article. Clinical Trial.
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB; MEASURE 2 Study Group. Sieper J, et al. Among authors: porter b. Ann Rheum Dis. 2017 Mar;76(3):571-592. doi: 10.1136/annrheumdis-2016-210023. Epub 2016 Aug 31. Ann Rheum Dis. 2017. PMID: 27582421 Clinical Trial.
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B; MEASURE 1 Study Group. Baraliakos X, et al. Among authors: porter b. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):50-55. Epub 2017 May 15. Clin Exp Rheumatol. 2018. PMID: 28516874 Free article. Clinical Trial.
Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis.
van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, Porter B, Readie A. van der Heijde D, et al. Among authors: porter b. Rheumatology (Oxford). 2019 Mar 1;58(3):388-400. doi: 10.1093/rheumatology/key128. Rheumatology (Oxford). 2019. PMID: 29860356 Free PMC article. Review.
Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.
Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK; MEASURE 2 study group. Deodhar A, et al. Among authors: porter b. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):260-269. Epub 2018 Jul 19. Clin Exp Rheumatol. 2019. PMID: 30148436 Clinical Trial.
854 results